Idera Pharma and BioCryst merger is terminated.

Idera Pharmaceuticals, Inc.announced that the Agreement and Plan of Merger and Reorganization (the �Merger Agreement�) entered into by and among Idera and BioCryst on January 22, 2018, has been terminated. The Merger Agreement was terminated following the July 10, 2018 special meeting of BioCryst stockholders at which BioCryst�s stockholders voted against the proposed mergers. Separately, a majority of Idera�s stockholders voted in favor of the adoption of the Merger Agreement at a special meeting of Idera stockholders, also held on July 10, 2018. As part of the merger agreement, BioCryst will reimburse Idera $6 million in connection with the termination.